Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.52 |
| ▸ | CCR5 | P51681 | 4/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592030 | 0.91 | TACR1 (0.43) | TACR1 | |
| SCHEMBL5446697 | 0.83 | TACR1 (0.49) | TACR1 | |
| SCHEMBL3590159 | 0.82 | TACR1 (0.60) | TACR1CCR5PDE4APDE4BPDE4C | |
| SCHEMBL13404386 | 0.82 | TACR1 (0.60) | TACR1CCR5PDE4APDE4BPDE4C | |
| SCHEMBL13404383 | 0.81 | TACR1 (0.74) | TACR1 | |
| SCHEMBL13404393 | 0.80 | TACR1 (0.56) | TACR1CCR5PDE4APDE4BPDE4C | |
| SCHEMBL13404349 | 0.80 | TACR1 (0.52) | TACR1CCR5PDE4APDE4BPDE4C | |
| SCHEMBL13404384 | 0.79 | TACR1 (0.56) | TACR1CCR5PDE4APDE4BPDE4C | |
| SCHEMBL13404398 | 0.77 | TACR1 (0.54) | TACR1CCR5PDE4APDE4BPDE4C | |
| SCHEMBL13404397 | 0.75 | TACR1 (0.51) | TACR1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383821-B2 | NK-1 and serotonin transporter inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-08 | — | — | US | disclosed |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087434-A1 | NK-1 and Serotonin Transporter Inhibitors | SLC6A4, TPH1, SLC6A2 | TACR1 19/4885CCR5 467/4885PDE4A 1748/4885 |
| US-20070249607-A1 | NK-1 AND SEROTONIN TRANSPORTER INHIBITORS | SLC6A4, TPH1, SLC6A2 | TACR1 19/4885CCR5 467/4885PDE4A 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.